INITIAL OBSERVATIONS ON EFFECT OF VIGABATRIN ON IN-VIVO H-1 SPECTROSCOPIC MEASUREMENTS OF GAMMA-AMINOBUTYRIC-ACID, GLUTAMATE, AND GLUTAMINE IN HUMAN BRAIN

Recent developments involving H-1 nuclear magnetic resonance (NMR) spectroscopic editing techniques have allowed noninvasive measurements of gamma-aminobutyric acid (GABA) in human cerebrum. The additional information gained from GABA and macromolecule measurements permitted more precise glutamate (Glu) and glutamine (Gin) measurements. Occipital lobe GABA in 10 nonepileptic, healthy subjects was 1.0 mu mol/g brain [95% confidence interval (CI) 0.9-1.1]. Vigabatrin (VGB) is a safe and effective antiepileptic drug (AED) that irreversibly inhibits neuronal and glial GABA-transaminase. GABA levels were increased in all patients treated with VGB. With a standard dose of 3-6 g/day, GABA levels were 2.6 mu mol/g (95% CI 2.3-2.8). Mean occipital GABA level measured in epileptic patients not receiving VGB was 0.9 mu mol/g (95% CI 0.7-1.1). Gln was increased by 1.9 mu mol/g and Glu was decreased by 0.8 mu mol/g in patients receiving VGB as compared with patients receiving standard medications alone.